DNM0904 is a novel antibiotic developed by DeNovaMed effective against Gram-positive bacteria (such as MRSA) and Gram-negative bacteria in conjunction with colistin. It has shown to perform exceptionally well versus multi-drug and colistin resistant strains. In tests, we determined the Minimum Inhibitory Concentration (MIC) of DNM 0904 against various Gram-positive strains and DNM0904/colistin for battling E. coli, K. pneumoniae, and A. baumannii. The MIC results were 0.01 – 0.03 in all cases, indicating highly effective performance.

Our ultimate goal is to leverage the strength of DNM0904 in combination with colistin to combat rising bacterial resistance and provide relief in terms of global economic loss and prevent potential setbacks in public health and industries. DNM0904 has been optimized for application in complex cases where other existing antibiotics are ineffective, bolstering our medical arsenal’s strength and responsiveness in future health-related crises.